Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry.
Edoardo FranciniKathryn P GrayGrace K ShawCarolyn P EvanAnis A HamidCaitlin E PerryPhilip W KantoffMary-Ellen TaplinChristopher J SweeneyPublished in: Prostate cancer and prostatic diseases (2019)
Using a single-institution registry, mCRPC patients treated since 2010 had a significant survival improvement vs. those treated before 2010. Although the median survival was only modestly improved and less than predicted when simply adding each newer drug survival advantage, the cumulative benefit from the new therapies was more pronounced in longer-term survivors and de-novo patients.